Immunic (IMUX) Update / Briefing Transcript

Immunic (IMUX) Update / Briefing April 30, 2025 08:00 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to Munich's webcast to discuss a wonderful update from our MS development program, the top line data of our Phase II CALIBER trial, fetoflunomyscalcium in progressive multiple sclerosis. My name is Jessica Bru, Vice President, Investor Relations and Communications here at Munich, and I will be the moderator for today's webcast. Please note that all participants will be in listen only mode and ...